Deep Tech Startups

Carroucell develops microcarrier technology for cell and gene therapy applications, enabling cost-effective bioproduction and cell amplification. The company serves the healthcare and biomanufacturing industries with sol-gel based microcarrier solutions.

1 investor

CARUS Bio develops gene delivery systems and cell-derived biologics for therapeutic applications. The company operates a healthcare division producing skincare and beverage products, while pursuing research in CAR-mRNA technology and therapeutic drug development.

1 investor

Cascade Geomatics provides persistent, automated 3D monitoring of geohazards in corridors and mountain environments, turning field sensor data into live digital twins and GIS-ready risk assessments. The platform is designed to enable early detection of ground movement for infrastructure and asset management.

1 investor

CatAmmon develops nano-ceramic catalysts intended to replace scarce platinum-group metals (PGMs) in applications such as automotive catalytic converters and ammonia cracking for hydrogen production. The company targets emission control systems and alternative energy markets with lower-cost, scalable advanced materials.

1 investor

Category Labs builds high-performance decentralized systems, including Monad, a fully EVM-compatible layer 1 blockchain designed for high throughput, fast block times, single-slot finality, and low hardware requirements. Its team draws on backgrounds in high-frequency trading and low-level systems engineering.

1 investor

CatSci is a contract research organization (CRO) providing drug development services — including catalyst screening, process chemistry, analytical development, oligonucleotides, peptides, and bioscience — to help biotech and pharma companies advance complex synthetic medicines from discovery to IND. It operates 14 laboratories across the UK and Europe and serves more than 100 biotech and global pharma customers.

1 investor

Cavigen develops 3D cell culture technology that standardizes organoid formation in defined microcavities and supports oxygen-sensing to better mimic tissue-like oxygen conditions. It targets researchers running 3D cell culture and drug testing workflows, working alongside existing laboratory instruments.

1 investor

Cbio develops next-generation T-cell therapies for solid tumors, which account for the majority of cancers. Its lead product, novoleucel, is a minimally invasive cell therapy designed to improve clinical outcomes and survival for late-stage cancer patients.

1 investor

Ceal develops carbon dioxide removal (CDR) technology designed to operate at gigaton scale by using existing industrial facility infrastructure. Its process is marketed as energy-efficient, additive- and emission-free, and independent of carbon markets, aimed at supporting net-zero goals.

1 investor

Cebina is an early-stage biotech investor and incubator that funds and de-risks pre-company and startup drug development projects across pre-seed, seed, and Series A stages. It focuses on therapeutic areas including cardiovascular and metabolic diseases, lung fibrosis, cancer immunotherapy, and anti-infectives, and also pursues co-development and licensing partnerships.</parameter> <parameter name="founders">[]

1 investor

CedarDB builds high-performance database systems designed for modern hardware such as multicore processors, memory, and fast storage. Spun off from the Technical University of Munich's Umbra research project in 2024, the company develops database technology for demanding data workloads.

1 investor

ceEntek is a global supplier of Ultra-High Performance Concrete (UHPC) products, offering advanced UHPC 2.0™ solutions for high-strength construction applications. The company serves the construction and infrastructure sectors across Asia, Middle East, North America, Europe, and Australia with precast elements, tunnel coatings, bridge components, and seismic retrofitting solutions.

1 investor

Celera Technologies designs custom analog integrated circuit (IC) solutions, using AI-accelerated workflows to replace legacy analog design flows and shorten delivery times. It serves chip and hardware developers seeking custom analog silicon.

1 investor

Celero Communications develops coherent DSP (digital signal processor) technology for high-bandwidth, low-power optical connections used in AI and data center infrastructure. Its platform provides scalable optical links between AI accelerators, servers, and clusters for accelerated computing.

1 investor

Cell Invent develops human disease models using reprogrammed Alzheimer patient cells to identify new therapeutic approaches for Alzheimer's disease. The company applies proprietary cellular research technology from Lund University to drug discovery and disease modeling for the neurodegenerative disease market.

1 investor

Cellarim produces beauty and skincare ingredients using enzymatic, cell-free synthesis rather than extraction, fermentation, or conventional chemical methods. It positions its enzyme-based approach as a way to make purer, more scalable, and more sustainable cosmetic ingredients.

1 investor

CellBri provides modular, automated cell processing systems for preparing cells for therapeutic applications. The company offers enclosed, turnkey solutions that can automate individual steps or complete workflows, from cell harvesting and separation through expansion and cryopreservation.

1 investor

CellCrine develops a chemically defined supplement (BAP-CDS) based on a Bio-Activated Protein, used as a serum-free replacement for Fetal Bovine Serum in cell culture across a wide range of cell types including stem cells, primary cells, and cell lines. The product targets researchers and cultivated-meat/biomanufacturing applications requiring chemically defined media.

1 investor

Cellcrypt develops quantum-safe secure communication platforms offering encrypted messaging, voice calls, and file transfers in multiple deployment models. The company serves enterprises, government agencies, and critical infrastructure organizations requiring quantum-resistant encryption and data sovereignty.

1 investor

Cellectis is a biotech company focused on cell therapy and immunotherapy. The company is publicly listed on Nasdaq and Euronext Growth Paris.

1 investor

IngenOx Therapeutics is a clinical-stage biopharmaceutical company developing precision drugs and cancer vaccines for patients with advanced, treatment-resistant cancers that evade the immune system. Based in Oxford, UK, it uses an in-house discovery platform for both small-molecule drug development and vaccine development targeting immunologically cold tumours.

1 investor

Cellestial Health is a preclinical-stage biotech developing therapies for Parkinson's disease, with a lead candidate rooted in astrocytic network biology. The company focuses on drug discovery for neurological disease.

1 investor

Cellfion develops materials for next-generation energy and water systems, focused on safer, higher-performance alternatives that reduce environmental impact. The company positions its work around sustainability and circular systems aligned with the UN Sustainable Development Goals.

1 investor

Cellpurics is a South Korean biotech company focused on stem cell technologies, including large-scale gonadal stem cell cultivation and storage, Real-time PCR-based measurement of mesenchymal stem cell anti-inflammatory capacity, and high-tech companion animal diagnostics. It also provides contract research organization (CRO) services covering in vitro and in vivo drug efficacy evaluation, veterinary drug and medical device clinical trials, GLP toxicity testing, and AI-based drug discovery.

1 investor